Co-Diagnostics fails quorum at annual meeting, adjourns to September 24
In focus for $CODX: Co-Diagnostics, Inc. failed to achieve a quorum at its Annual Meeting of Stockholders on September 3, 2026, leaving all scheduled business untransacted. The company adjourned the meeting to September…
Key takeaways
- Co-Diagnostics, Inc. ($CODX) failed to achieve a quorum at its Annual Meeting of Stockholders on September 3, 2026, leaving all scheduled business untransacted.
- The meeting was adjourned to September 24, 2026, at 9:00 a.m. Mountain Time at the company's Salt Lake City, Utah offices at 2401 S. Foothill Drive, Suite D.
- The 8-K, filed September 4 and signed by CEO Dwight Egan, offers no explanation for why the meeting fell short of quorum.
- Proxies submitted ahead of the September 3 meeting remain valid at the reconvened session unless a holder formally changes or revokes them before votes are taken.
- The company's bylaws permit further adjournment if the September 24 meeting also fails to reach quorum, which would extend the shareholder vote past this month.
In focus for $CODX: Co-Diagnostics, Inc. failed to achieve a quorum at its Annual Meeting of Stockholders on September 3, 2026, leaving all scheduled business untransacted. The company adjourned the meeting to September 24, 2026, at 9:00 a.m. Mountain Time, when stockholders will reconvene at the company's Salt Lake City, Utah offices at 2401 S. Foothill Drive, Suite D.
A quorum failure does not register on the tape the way a guidance cut or a deal close does. It does carry a read on where the float actually is relative to the vote, and the 8-K, filed September 4 and signed by CEO Dwight Egan as principal executive officer, offers no explanation for why the meeting fell short. The procedural record ends there.
Co-Diagnostics' bylaws give the meeting chairperson authority to adjourn when quorum is absent, without requiring additional formal notice beyond the announcement made at the meeting. That provision moved the date to the 24th. The agenda and vote terms carry over from the definitive proxy statement the company filed with the SEC on July 21, 2026.
What carries forward to September 24
Proxies submitted ahead of the September 3 meeting remain valid at the reconvened session unless a holder formally changes or revokes them before votes are taken. Stockholders who have not yet submitted a proxy can still do so before the 24th.
The setup heading into September 24 is straightforward. Co-Diagnostics needs to hit quorum to conduct any business. Its bylaws permit further adjournment if the 24th comes up short again, which would extend the window on the shareholder vote past this month. The filing gives no indication whether the company plans additional outreach to holders in the weeks between now and then.
The next confirmable event is the reconvened meeting on September 24, 2026, at 9:00 a.m. Mountain Time in Salt Lake City.